Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US

被引：0

作者：

Khanani, Arshad M. ^{[1
,2
]}

Dugel, Pravin U. ^{[3
,4
]}

Haller, Julia A. ^{[5
]}

Wagner, Alan L. ^{[6
,7
]}

Lescrauwaet, Benedicte ^{[8
]}

Schmidt, Ralph ^{[9
,10
]}

Bennison, Craig ^{[11
]}

机构：

[1] Sierra Eye Associates, Reno, NV 89502 USA

[2] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA

[3] Retina Consultants Arizona, Phoenix, AZ 85053 USA

[4] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90033 USA

[5] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA

[6] Wagner Macula & Retina Ctr, Virginia Beach, VA 23454 USA

[7] Eastern Virginia Med Sch, Dept Ophthalmol, Virginia Beach, VA 23456 USA

[8] Xintera Bvba, Ghent, Belgium

[9] Tilburg Univ, Dept Cognit Sci & Artificial Intelligence, Tilburg, Netherlands

[10] Pharmerit Int, Berlin, Germany

[11] Pharmerit Int, York, N Yorkshire, England

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 04期

关键词：

cost; ocriplasmin; symptomatic vitreomacular adhesion; vitreomacular traction; VISUAL-ACUITY; INTRAVITREAL OCRIPLASMIN; 15-YEAR PERIOD; MACULAR HOLE; TRACTION; POPULATION; HEALTH; SIMULATION; VITRECTOMY; DATABASE;

D O I：

10.2217/cer-2019-0117

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: Evaluate the cost-effectiveness of ocriplasmin in symptomatic vitreomacular adhesion (VMA) with or without full-thickness macular hole <= 400 mu m versus standard of care. Methods: A state-transition model simulated a cohort through disease health states; assignment of utilities to health states reflected the distribution of visual acuity. Efficacy of ocriplasmin was derived from logistic regression models using Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole trial data. Model inputs were extracted from Phase III trials and published literature. The analysis was conducted from a US Medicare perspective. Results: Lifetime incremental cost-effectiveness ratio was US$4887 per quality-adjusted life year gained in the total population, US$4255 and US$10,167 in VMA subgroups without and with full-thickness macular hole, respectively. Conclusion: Ocriplasmin was cost effective compared with standard of care in symptomatic VMA.

引用

页码：287 / 306

页数：20

共 54 条

[1] [Anonymous], 2013, GUID METH TECHN APPR
[2] Arias E, 2016, NATL VITAL STAT REP, V65, P8
[3] Bandello F, 2019, 5 SAN RAFF OCT RET F
[4] Bennison C, 2016, J MARK ACCESS HLTH P, V4:1-11
[5] Brändle M, 2007, INT J CLIN PHARM TH, V45, P203
[6] PREVALENCE OF METAMORPHOPSIA IN PATIENTS WITH VITREOMACULAR TRACTION, WITH OR WITHOUT MACULAR HOLE, AND ITS IMPACT ON QUALITY OF LIFE: THE MEMO STUDY
Brazier, J.
Hirneiss, C.
Tangelder, M.
Lescrauwaet, B.
Patel, P.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A126 - A126
[7] A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration
Brown, Gary C.
Brown, Melissa M.
Brown, Heidi C.
Kindermann, Sylvia
Sharma, Sanjay
[J]. OPHTHALMOLOGY, 2007, 114 (06) : 1170 - 1178
[8] Incremental cost-effectiveness of initial cataract surgery
Busbee, BG
Brown, MM
Brown, GC
Sharma, S
[J]. OPHTHALMOLOGY, 2002, 109 (03) : 606 - 612
[9] Canadian Agency for Drugs and Technologies in Health (CADTH), 2014, COMM DRUG REV CLIN R
[10] Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
Caro, J. Jaime
Briggs, Andrew H.
Siebert, Uwe
Kuntz, Karen M.
[J]. VALUE IN HEALTH, 2012, 15 (06) : 796 - 803

← 1 2 3 4 5 6 →